Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $33.98 million. The enterprise value is $30.93 million.
| Market Cap | 33.98M |
| Enterprise Value | 30.93M |
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.86 million shares outstanding. The number of shares has increased by 4.06% in one year.
| Current Share Class | 10.86M |
| Shares Outstanding | 10.86M |
| Shares Change (YoY) | +4.06% |
| Shares Change (QoQ) | -1.91% |
| Owned by Insiders (%) | 13.37% |
| Owned by Institutions (%) | 44.14% |
| Float | 8.82M |
Valuation Ratios
The trailing PE ratio is 44.07 and the forward PE ratio is 53.23.
| PE Ratio | 44.07 |
| Forward PE | 53.23 |
| PS Ratio | 1.78 |
| Forward PS | 2.14 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 3.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 39.86 |
| EV / Sales | 1.62 |
| EV / EBITDA | 38.52 |
| EV / EBIT | 45.69 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.55 |
| Quick Ratio | 2.98 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | n/a |
| Interest Coverage | 677.00 |
Financial Efficiency
Return on equity (ROE) is 7.76% and return on invested capital (ROIC) is 9.87%.
| Return on Equity (ROE) | 7.76% |
| Return on Assets (ROA) | 3.31% |
| Return on Invested Capital (ROIC) | 9.87% |
| Return on Capital Employed (ROCE) | 6.01% |
| Weighted Average Cost of Capital (WACC) | 12.13% |
| Revenue Per Employee | $531,222 |
| Profits Per Employee | $21,556 |
| Employee Count | 36 |
| Asset Turnover | 1.50 |
| Inventory Turnover | 2.75 |
Taxes
In the past 12 months, Nephros has paid $12,000 in taxes.
| Income Tax | 12,000 |
| Effective Tax Rate | 1.52% |
Stock Price Statistics
The stock price has decreased by -19.12% in the last 52 weeks. The beta is 1.49, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -19.12% |
| 50-Day Moving Average | 3.25 |
| 200-Day Moving Average | 4.18 |
| Relative Strength Index (RSI) | 41.80 |
| Average Volume (20 Days) | 19,054 |
Short Selling Information
The latest short interest is 25,295, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 25,295 |
| Short Previous Month | 21,191 |
| Short % of Shares Out | 0.23% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
In the last 12 months, Nephros had revenue of $19.12 million and earned $776,000 in profits. Earnings per share was $0.07.
| Revenue | 19.12M |
| Gross Profit | 11.46M |
| Operating Income | 677,000 |
| Pretax Income | 788,000 |
| Net Income | 776,000 |
| EBITDA | 803,000 |
| EBIT | 677,000 |
| Earnings Per Share (EPS) | $0.07 |
Balance Sheet
The company has $4.02 million in cash and $968,000 in debt, with a net cash position of $3.05 million or $0.28 per share.
| Cash & Cash Equivalents | 4.02M |
| Total Debt | 968,000 |
| Net Cash | 3.05M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 10.70M |
| Book Value Per Share | 0.99 |
| Working Capital | 8.97M |
Cash Flow
| Operating Cash Flow | -348,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 126,000 |
| Net Borrowing | -5,000 |
| Free Cash Flow | -348,000 |
| FCF Per Share | -$0.03 |
Margins
Gross margin is 59.95%, with operating and profit margins of 3.54% and 4.06%.
| Gross Margin | 59.95% |
| Operating Margin | 3.54% |
| Pretax Margin | 4.12% |
| Profit Margin | 4.06% |
| EBITDA Margin | 4.20% |
| EBIT Margin | 3.54% |
| FCF Margin | n/a |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.06% |
| Shareholder Yield | -4.06% |
| Earnings Yield | 2.28% |
| FCF Yield | -1.02% |
Analyst Forecast
The average price target for Nephros is $7.00, which is 123.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.00 |
| Price Target Difference | 123.64% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -4.08 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.08 |
| Piotroski F-Score | 3 |